Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > COLUMN
COLUMN
- Watch out for the Gorilla when Hiring Talent
July 19, 2013
- Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
- Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
May 23, 2013
- An Insider’s Perspective on Hiring in Japan
April 26, 2013
- Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
- Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
- Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
- What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
- Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
- Leading from Afar
October 22, 2012
- “Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
- Our Habits Determine Our Success
August 8, 2012
- Marketing Is More than a Pen and a Tissue Box
July 9, 2012
- Science without Works Is Dead
June 4, 2012
- Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
- The Eight Characteristics of a Great Leader
April 2, 2012
- Maurer’s Healthcare Insight (143)
March 26, 2012
- Maurer’s Healthcare Insight (142)
February 27, 2012
- Maurer’s Healthcare Insight (141)
January 30, 2012
- Maurer’s Healthcare Insight (140)
December 26, 2011
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…